N4 Pharma reassures shareholders over future of 'Nuvec'
15th Apr 2019 15:33
(Sharecast News) - Specialist pharmaceutical company N4 Pharma updated the market on the development of 'Nuvec' on Monday, following the disclosure of inconsistencies in the efficacy of Nuvec between various in vitro and in vivo studies.
Read moreN4 Pharma raises £1.05m in placing to advance vaccine delivery system
8th Feb 2019 12:00
(Sharecast News) - Specialist pharmaceutical company N4 Pharma said on Friday that it has raised £1.05m before expenses in a placing of 10.5m new ordinary shares to fund its vaccine delivery system.
Read moreN4 Pharma extends 'Nuvec' licence agreement with Aussie university firm
20th Dec 2018 15:06
(Sharecast News) - Specialist pharmaceutical company N4 Pharma has extended the terms of its licence agreement with UniQuest - a University of Queensland company - for the exploitation of its novel delivery system 'Nuvec' on Thursday.
Read moreN4 Pharma bears more good news on its Nuvec particles
28th Nov 2018 11:30
(Sharecast News) - Specialist pharmaceutical company N4 Pharma updated on the latest key research findings for its 'Nuvec' delivery system on Wednesday.
Read moreN4 Pharma pleased with latest test results on 'Nuvec'
29th Oct 2018 11:32
(Sharecast News) - Specialist pharmaceutical company N4 Pharma updated the market on the latest key research findings for its 'Nuvec' delivery system on Monday, reporting that the Nuvec particles had a "clear adjuvant effect" to help deliver a level of immune response for both the mRNA and pDNA OVA antigens, comparable to that of existing delivery systems.
Read moreN4 Pharma calls it a day on generics division, losses widen
20th Sep 2018 09:49
(Sharecast News) - After undertaking a strategic review, N4 Pharma directors have decided to discontinue further development of Sildenafil and shutter the rest of its generics division.
Read more